Cuick Trac Enclave Powers Beryllium InfoSec to CMMC Level 2 Certification
DALLAS--(BUSINESS WIRE)--Beryllium InfoSec, Inc., a cybersecurity and compliance firm serving the Defense Industrial Base (DIB), has officially achieved Cybersecurity Maturity Model Certification (CMMC) Level 2 using its flagship solution, Cuick Trac, a FedRAMP Moderate Equivalent, fully managed enclave-as-a-service.
This milestone demonstrates that Beryllium's internal information system, powered by Cuick Trac, meets the Department of Defense's rigorous standards for protecting Controlled Unclassified Information (CUI). The certification was granted following a formal third-party assessment.
A Certified Environment, Not Just a Product
CMMC Level 2 certifies an organization's information system, not a standalone tool or platform. Cuick Trac provides the secure foundation, architecture, and documentation necessary for assessment readiness. It is the complete integration of people, process, and technology that achieves certification. By undergoing its own full CMMC Level 2 assessment, Beryllium validated that Cuick Trac can serve as the cornerstone of a certifiable environment.
In addition to supporting CMMC certification, Cuick Trac has achieved FedRAMP Ready status, a designation reviewed and approved by the FedRAMP Program Management Office. This distinction reflects the platform's maturity and readiness for organizations requiring cloud solutions that meet federal security standards.
Why This Matters to Contractors
Contractors handling or pursuing CUI-related contracts must prove they meet CMMC Level 2 standards. Cuick Trac helps them do so faster and with less complexity by providing a managed, assessment-ready platform.
Organizations using Cuick Trac inherit key elements of a certified environment, reducing the burden of configuring and maintaining multiple disjointed tools. Both FedRAMP Moderate Equivalency and CMMC Level 2 readiness are embedded into the Cuick Trac experience.
How Cuick Trac Helps Organizations Align with CMMC Level 2
Secure enclave mapped to NIST SP 800-171 and DFARS 252.204-7012
Inherited controls with a clearly defined customer responsibility matrix
Red team-tested, STIG-hardened, FedRAMP Moderate Equivalent architecture
Advisory services to support POA&M development, SSP documentation, and audit readiness
Endpoint security guidance, including strategies for VDI scoping and risk reduction
From the Leadership Team
'Cuick Trac has been penetration tested, red-teamed, and assessed by both FedRAMP and CMMC auditors with perfect scores. That is the kind of environment you want protecting your CUI.'
— Jeff Baldwin, Chief Information Security Officer
'This is what it means to lead by example. To go above and beyond the mission. To make 'CMMC-ready' more than a slogan.'
— George Perezdiaz, Director of Compliance Advisory
"Our mission at Beryllium is to empower the companies that help keep us safe. One of the main ways we do this is by simplifying cybersecurity and compliance for hundreds of federal contractors with our Cuick Trac Managed Enclave. Achieving CMMC Level 2 marks a massive milestone in our journey since launching Cuick Trac over seven years ago. I could not be prouder of our team – this achievement reflects thousands of hours of dedication, precision, and deep expertise in cybersecurity and compliance. Achieving FedRAMP Moderate and now CMMC Level 2 was not just about checking boxes. It was about proving that our team, our solution, and our process meet and exceed the rigorous standards we support our customers through every day."
— Lincoln Neely, CEO
Ongoing Commitment
This achievement underscores Cuick Trac's broader mission: to simplify compliance without oversimplifying what real security requires.
Cuick Trac will continue to evolve in response to Department of Defense expectations, including support for emerging frameworks such as SBOM management, Zero Trust Architecture (ZTA) principles, and NIST 800-160 Volume 2.
About Beryllium InfoSec
Beryllium InfoSec, Inc., headquartered in Dallas, Texas, is a cybersecurity and compliance firm specializing in helping organizations navigate and satisfy complex security frameworks. Since 2017, Beryllium has delivered expert guidance and tailored solutions, including its flagship platform Cuick Trac, to help organizations achieve and maintain compliance with CMMC, NIST SP 800-171, DFARS, and FedRAMP requirements.
About the Cuick Trac Solution
Cuick Trac is a fully managed CUI enclave and compliance platform built for defense contractors, primes, and suppliers in the Defense Industrial Base. With built-in controls, expert advisory services, and a FedRAMP Moderate Equivalent foundation, Cuick Trac enables faster and more confident alignment with DFARS, NIST, and CMMC frameworks.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Confused by latest order? How to calculate if your Jackson County assessment is within limits
KANSAS CITY, Mo. — Jackson County assessments are showing up in homeowner's mailboxes. Some people may be surprised at the increase after a May order from the State Tax Commission. Some taxpayers may receive tax refunds in June: When payments could arrive That order capped increases in each assessment period at 15% and set 2022 as a starting point for this year's assessments after 2023 assessments were heavily contested. But determining your maximum 2025 assessment is a little bit more complicated than a single multiplication or division. Legislator Sean Smith and Preston Smith (no relation) have been helping homeowners with appeals since assessments skyrocketed in 2023. This week as they went out again they've been getting questions about what the latest State Tax Commission Order and 15% cap really means. 'People look at it and the first thing they see is, I thought it was only going to be a 15% increase and that was the perception. I've probably answered it online 100 times,' Preston Smith said. 'A lot of people are contacting me thinking they only do the 15 percent once, but you have to do it twice,' Legislator Sean Smith explained. To illustrate how it works with the latest rules using 2022 assessments as the starting point, consider a home with a $100,000 assessed value in 2022. To calculate the maximum assessed value in 2023 multiply $100,000 by 1.15 which is $115,000. But then you have to multiply by 115% again to determine the maximum value a home could be assessed at this year. In this example it would be $132,250. The two 15% increases end up yielding a maximum increase of 32.25% during the two assessment periods. 'I would really urge people to do the math themselves to check it, check and really verify,' Preston Smith said. To do that, however, you have to know your home's 2022 assessed value, which according to those who have received this year's assessments, isn't on this year's notices. You can find that historical information online at the Jackson County Parcel Viewer or Ascend Web. If your increase ends up beyond the allowances under the State order or if you simply don't agree with your value, you still can appeal. Appeals have to be filed by July 14. Download WDAF+ for Roku, Fire TV, Apple TV As for seniors, 40,000 are already enrolled in a new tax credit program freezing tax bills. The county says estimated savings are included on notices, but are subject to change. Both Sean and Preston Smith say they are pressing the Assessor's Office for complete assessment data in 2022, 2023 and 2025 to see how much home values increased, and how many of those increases equated to the maximum allowed if no new construction was done under the State Tax Commission Order without a physical inspection. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
6 hours ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
